NB-UVB 311 nm in Vitiligo: Dosing Protocols, Cohort Outcomes, and Practical Tips
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best responses on face/neck, slower on acral sites. Start low, escalate by 10–20% […]
Patient-Reported Outcomes in Vitiligo: DLQI, Vitiligo-Specific Scales, and What Counts as Clinically Meaningful
Key Takeaways Why PROMs? Pigment changes affect visibility, stigma, and function. PROMs help prioritize sites (e.g., face/hands) and set goals
Vitiligo Combination Algorithms: NB-UVB / Excimer 308 + Topicals (Steroids, Calcineurin Inhibitors, JAK) by Site
Key Takeaways Face/neck: NB-UVB or excimer + tacrolimus 0.1% is first-line; consider label-eligible topical JAK for added speed in limited
Surgical Options Beyond MKTP in Vitiligo: Suction Blister, Punch/Minigrafting, and FUE-Grafting
Key Takeaways Stability first: no new/enlarging macules for ≥6–12 months, quiet Wood’s-lamp rim, and no Koebner activity. Best sites: face/neck
Differential Diagnosis of Vitiligo: Common Look-Alikes, Wood’s Lamp Hints, and Dermoscopy Cues
Key Takeaways Vitiligo shows chalk-/blue-white accentuation on Wood’s lamp with sharp borders and possible perifollicular islands. Scale, itch, or coppery/yellow
Vitiligo Comorbidities & Labs: Thyroid, Autoantibodies, Vitamin D, and a Practical Screening Algorithm
Key Takeaways Most actionable comorbidity: autoimmune thyroid disease (subclinical → overt). Start with TSH, reflex to FT4 if abnormal; add
Vitiligo Relapse & Maintenance: TRM Biology and Practical Therapy Schemes
Key Takeaways Relapse is driven by tissue-resident memory T cells (TRM) and the IFN-γ–CXCL9/10 chemokine loop that re-recruits cytotoxic T
Pediatric Vitiligo: Therapy, Safety, and Phototherapy Protocols
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB
Segmental vs Nonsegmental Vitiligo: Clinical Patterns, Prognosis, and Treatment Strategy
Key Takeaways Segmental vitiligo (SV): unilateral/dermatomal clusters, rapid early spread then stability, frequent leukotrichia, limited systemic autoimmunity, best long-term results